Ir para o conteúdo principal

Organogenesis (NYSE: ORGO) — Perfil da empresa, notícias e dados financeiros

Logo de Organogenesis
ORGO Organogenesis
Organogenesis primary media
Perfil da empresa

Organogenesis

Organogenesis (NASDAQ:ORGO) specializes in regenerative medicine, focusing on the development, manufacturing, and commercialization of solutions for the advanced wound care, surgical, and sports medicine markets. Its portfolio encompasses a wide range of products designed to facilitate the body's own healing process. The company is dedicated to improving patient outcomes and reducing healthcare costs through its innovative therapies. With a strong commitment to research and development, Organogenesis aims to expand its product offerings and explore new applications for its regenerative medicine technologies. By continuously advancing the field of regenerative medicine, Organogenesis seeks to address unmet medical needs and enhance the quality of life for patients around the world.

Resumo

Public USParticipação acionária
1985Ano de fundação
862Funcionários
Canton, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Organogenesis

  • Apligraf, a bio-engineered skin substitute for treating venous leg ulcers and diabetic foot ulcers.
  • PuraPly Antimicrobial (AM), which manages bioburden in wounds and supports healing.
  • Affinity, a porcine-derived skin graft used in wound management for non-healing wounds.
  • NuShield, a placental-derived tissue product that aids in the management of surgical wounds.
  • ReNu, a cryopreserved amniotic suspension allograft for the management of symptoms associated with knee osteoarthritis.
  • BioVance, an amniotic membrane allograft that supports wound closure in various types of wounds.

equipe executiva do Organogenesis

  • Gary S. Gillheeney Sr.President, CEO, Chair of the Board
  • David C. FranciscoChief Financial Officer
  • Patrick BilboChief Operating Officer
  • Lori H. FreedmanChief Administrative & Legal Officer
  • Brian GrowChief Commercial Officer
  • Patrick McGuireChief Accounting Officer
  • Robert CavorsiChief Business Officer
  • William R. KolbSecretary

Principais indicadores financeiros

Resultados divulgados pela Organogenesis, em USD.

Cap. de mercado
104,2 mi
Receita (TTM)
352 mi
P/L
—
LPA (diluído, TTM)
-1.2
Dividend yield
—
Margem de lucro
-38.5%
Receita e lucro anuais da Organogenesis
Fim do ano fiscalReceitaResultado operacionalLucro líquido
563 mi55,9 mi37 mi
482 mi-1,3 mi861 mil
433,1 mi12,5 mi4,9 mi
450,9 mi22,3 mi15,5 mi